Adagene (ADAG) to Release Earnings on Monday

Adagene (NASDAQ:ADAG) is expected to post its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 1:30 PM ET.

Adagene Trading Up 16.0%

Shares of NASDAQ:ADAG opened at $4.13 on Monday. The business’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $2.19. Adagene has a one year low of $1.30 and a one year high of $4.58.

Analysts Set New Price Targets

A number of analysts recently commented on ADAG shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adagene in a research note on Wednesday, January 21st. Guggenheim assumed coverage on shares of Adagene in a research note on Monday, November 24th. They issued a “buy” rating and a $9.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Adagene presently has a consensus rating of “Buy” and a consensus target price of $7.67.

Hedge Funds Weigh In On Adagene

Several large investors have recently added to or reduced their stakes in ADAG. Marex Group plc purchased a new stake in Adagene in the second quarter valued at approximately $47,000. SmartHarvest Portfolios LLC acquired a new position in shares of Adagene in the 4th quarter valued at $73,000. Citadel Advisors LLC purchased a new stake in shares of Adagene during the 3rd quarter valued at $80,000. Finally, Exome Asset Management LLC purchased a new stake in shares of Adagene during the 4th quarter valued at $2,004,000. 9.51% of the stock is currently owned by hedge funds and other institutional investors.

About Adagene

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.